Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism

This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.

Official registry: https://clinicaltrials.gov/study/NCT07752511 · Hacettepe University · enrollment listed as 90

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 90 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

The Impact of Anticipated Illness Stigma and Illness Identity on Quality of Life in Men With Hypogonadism: A Comparative Study With Other Chronic Endocrine Diseases

Primary outcome (registry wording): Chronic Illness Anticipated Stigma Scale (CIASS) Score

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Men only
  • Male, aged 18 years or older
  • Biochemically confirmed hypogonadism (total testosterone \< 300 ng/dL with at least one clinical symptom)
  • Regular follow-up at the endocrinology outpatient clinic
  • Fluent in reading and understanding Turkish
  • Diagnosed with diabetes, hypertension, or hypothyroidism under regular endocrinology follow-up
  • Total testosterone ≥ 300 ng/dL
  • Age-matched to a participant in the case group (±5 years)

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

2 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Natural History of Sickle Cell Disease

This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.

NCT00081523 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

FAQ about this NCT record

Is NCT07752511 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07752511?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07752511?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary